Lupin Receives USFDA Approval for Generic Bromfenac Ophthalmic Solution

17 Aug 2023 , 11:35 AM

Pharma giant Lupin announced on Wednesday that the US health agency had given the go-ahead for the marketing of its generic form of Bromfenac Ophthalmic Solution, which is used to treat post-operative inflammation in people who have had cataract surgery. 

According to a regulatory filing by Lupin, the US Food and Drug Administration (USFDA) has approved the abbreviated new drug application for bromfenac ophthalmic solution 0.09%.

According to the statement, the item is a generic version of Bausch + Lomb’s Bromday Ophthalmic Solution, 0.09%.

According to the business, the medicine would be produced at Lupin’s Pithampur factory in Madhya Pradesh.

According to Lupin, who cited IQVIA MAT statistics for June, Bromfenac Ophthalmic Solution 0.09 percent had anticipated annual sales worth USD 11 million in the US.

For feedback and suggestions, write to us at [e-mail]